Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis
dc.contributor.author | Kandarpa, Malathi | |
dc.contributor.author | Wu, Yi‐mi | |
dc.contributor.author | Robinson, Dan | |
dc.contributor.author | Burke, Patrick William | |
dc.contributor.author | Chinnaiyan, Arul M. | |
dc.contributor.author | Talpaz, Moshe | |
dc.date.accessioned | 2017-05-10T17:49:09Z | |
dc.date.available | 2018-08-07T15:51:22Z | en |
dc.date.issued | 2017-06 | |
dc.identifier.citation | Kandarpa, Malathi; Wu, Yi‐mi ; Robinson, Dan; Burke, Patrick William; Chinnaiyan, Arul M.; Talpaz, Moshe (2017). "Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis." American Journal of Hematology 92(6): 555-561. | |
dc.identifier.issn | 0361-8609 | |
dc.identifier.issn | 1096-8652 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/136751 | |
dc.description.abstract | Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell (HSC) disorders that can be classified on the basis of genetic, clinical, phenotypic features. Genetic lesions such as JAK2 mutations and BCRâ ABL translocation are often mutually exclusive in MPN patients and lead to essential thrombocythemia, polycythemia vera, or myelofibrosis or chronic myeloid leukemia, respectively. Nevertheless, coexistence of these genetic aberrations in the same patient has been reported. Whether these aberrations occur in the same stem cell or a different cell is unclear, but an unstable genome in the HSCs seems to be the common antecedent. In an effort to characterize the underlying genetic events that might contribute to the appearance of more than one MPN in a patient, we studied neoplastic cells from patients with dual MPNs by nextâ generation sequencing. We observed that most patients with two MPNs harbored mutations in genes known to contribute to clonal hematopoiesis through altered epigenetic regulation such as TET2, ASXL1/2, SRSF2, and IDH2 at varying frequencies (1%â 47%). In addition, we found that some patients also harbored oncogenic mutations in N/KRAS, TP53, BRAF, EZH2, and GNAS at low frequencies, which probably represent clonal evolution. These findings support the hypothesis that hematopoietic cells from MPN patients harbor multiple genetic aberrations, some of which can contribute to clonal dominance. Acquiring mutations in JAK2/CALR/MPL or the BCRâ ABL translocation probably drive the oncogenic phenotype towards a specific MPN. Further, we propose that the acquisition of BCRâ ABL in these patients is frequently a secondary event resulting from an unstable genome. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.title | Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbsecondlevel | Molecular, Cellular and Developmental Biology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.subject.hlbtoplevel | Science | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/136751/1/ajh24728.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/136751/2/ajh24728_am.pdf | |
dc.identifier.doi | 10.1002/ajh.24728 | |
dc.identifier.source | American Journal of Hematology | |
dc.identifier.citedreference | Soverini S, de Benedittis C, Mancini M, et al. Mutations in the BCRâ ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2015; 15Suppl: S120 12â S128. | |
dc.identifier.citedreference | Hassan A, Dogara LG, Babadoko AA, et al. Coexistence of JAK2 and BCRâ ABL mutation in patient with myeloproliferative neoplasm. Niger Med J. 2015; 56: 74 â 76. | |
dc.identifier.citedreference | Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCRâ ABL junction and JAK2V617F mutation. Leukemia. 2008; 22: 1059 â 1062. | |
dc.identifier.citedreference | Wang X, Tripodi J, Kremyanskaya M, et al. BCRâ ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood. 2013; 121: 1238 â 1239. | |
dc.identifier.citedreference | Yamada O, Mahfoudhi E, Plo I, et al. Emergence of a BCRâ ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCRâ ABL in the JAK2V617F clone. J Clin Oncol. 2014; 32: e76 â e79. | |
dc.identifier.citedreference | Martinâ Cabrera P, Haferlach C, Kern W, et al. BCRâ ABL1â positive and JAK2 V617Fâ positive clones in 23 patients with both aberrations reveal biologic and clinical importance. Br J Haematol. 2017; 176: 135 â 139. | |
dc.identifier.citedreference | Cambier N, Renneville A, Cazaentre T, et al. JAK2V617Fâ positive polycythemia vera and Philadelphia chromosomeâ positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia. 2008; 22: 1454 â 1455. | |
dc.identifier.citedreference | Cieslik M, Chugh R, Wu YM, et al. The use of exome capture RNAâ seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res. 2015; 25: 1372 â 1381. | |
dc.identifier.citedreference | Mody RJ, Wu YM, Lonigro RJ, et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA. 2015; 314: 913 â 925. | |
dc.identifier.citedreference | Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161: 1215 â 1228. | |
dc.identifier.citedreference | Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in tripleâ negative essential thrombocythemia patients. Blood. 2016; 127: 333 â 342. | |
dc.identifier.citedreference | Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014; 123: 2220 â 2228. | |
dc.identifier.citedreference | Magor GW, Tallack MR, Klose NM, et al. Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAKâ STAT Signaling and Epigenetic Regulation. J Mol Diagn. 2016; 18: 707 â 718. | |
dc.identifier.citedreference | Zhang L, Singh RR, Patel KP, et al. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wildâ type RAS. Am J Hematol. 2014; 89: 499 â 504. | |
dc.identifier.citedreference | Link DC, Walter MJ. CHIP’ping away at clonal hematopoiesis. Leukemia. 2016; 30: 1633 â 1635. | |
dc.identifier.citedreference | Stein BL, Williams DM, O’keefe C, et al. Disruption of the ASXL1 gene is frequent in primary, postâ essential thrombocytosis and postâ polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011; 96: 1462 â 1469. | |
dc.identifier.citedreference | Abdelâ Wahab O, Adli M, LaFave Lindsay M, et al. ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2â Mediated Gene Repression. Cancer Cell. 2012; 22: 180 â 193. | |
dc.identifier.citedreference | Kameda T, Shide K, Yamaji T, et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood. 2015; 125: 304 â 315. | |
dc.identifier.citedreference | Trifa AP, Popp RA, Cucuianu A, et al. Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms. Leuk Lymphoma. 2012; 53: 2496 â 2497. | |
dc.identifier.citedreference | Chung SS, Kim E, Park JH, et al. Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia. Sci Transl Med. 2014; 6: 238ra271 â 238ra271. | |
dc.identifier.citedreference | Innamorati G, Valenti MT, Giacomello L, et al. GNAS Mutations: Drivers or Coâ Pilots? Yet, Promising Diagnostic Biomarkers. Trends Cancer. 2: 282 â 285. | |
dc.identifier.citedreference | Grisouard J, Ojedaâ Uribe M, Looser R, et al. Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia. Blood. 2013; 122: 3694 â 3696. | |
dc.identifier.citedreference | Pieri L, Spolverini A, Scappini B, et al. Concomitant occurrence of BCRâ ABL and JAK2V617F mutation. Blood. 2011; 118: 3445 â 3446. | |
dc.identifier.citedreference | Xu N, Ding L, Yin C, et al. A report on the coâ occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients. Ann Hematol. 2015; 94: 865 â 867. | |
dc.identifier.citedreference | Zhou A, Knoche EM, Engle EK, et al. Concomitant JAK2 V617Fâ positive polycythemia vera and BCRâ ABLâ positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J. 2015; 5: e351 | |
dc.identifier.citedreference | Jaiswal S, Fontanillas P, Flannick J, et al. Ageâ Related Clonal Hematopoiesis Associated with Adverse Outcomes. N Engl J Med. 2014; 371: 2488 â 2498. | |
dc.identifier.citedreference | Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127: 2391 â 2405. | |
dc.identifier.citedreference | Jamieson CH. Chronic Myeloid Leukemia Stem Cells. Hematology Am Soc Hematol Educ Program. 2008; 2008: 436 â 442. | |
dc.identifier.citedreference | Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369: 2379 â 2390. | |
dc.identifier.citedreference | Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and pointâ ofâ care diagnostic algorithms. Leukemia. 2007; 22: 14 â 22. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.